MedTrace Logo

Rifaximin Treatment of Papulopustular Rosacea

NCT01359228 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2014-04-28

No results posted yet for this study

Summary

The purpose of this study is to determine the effects of rifaximin on skin symptoms in patients with rosacea by double-blinded, placebo-controlled, crossover study.

Conditions

  • Rosacea

Interventions

DRUG

Rifaximin (XIFAXAN)

Rifaximin (XIFAXAN®) 1650 mg/day (550 mg tablet three times a day) for 14 days

DRUG

Placebo

Placebo 1 tablet three times a day for 14 days.

Sponsors & Collaborators

Principal Investigators

  • Martin Steinhoff, MD, Ph.D. · UCSF, Dept. of Dermatology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2014-06-30
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01359228 on ClinicalTrials.gov